(Q38639542)

5 September 2017

Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1. (English)

1 reference

Mycobacterium tuberculosis

5 September 2017

1 reference

1 reference

1 reference

Hanki Lee

1

1 reference

PubMed ID

26586403

5 September 2017

Joo-Won Suh

series ordinal

2

1 reference

5 September 2017

19 November 2015

1 reference

Journal of Industrial Microbiology & Biotechnology

5 September 2017

1 reference

5 September 2017

43

1 reference

5 September 2017

205-212

1 reference

5 September 2017

2-3

1 reference

Structural mechanism for rifampicin inhibition of bacterial rna polymerase

5 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Discovery and characterization of the tuberculosis drug lead ecumicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Lassomycin, a Ribosomally Synthesized Cyclic Peptide, Kills Mycobacterium tuberculosis by Targeting the ATP-Dependent Protease ClpC1P1P2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Mycobacterium tuberculosis ClpC1: characterization and role of the N-terminal domain in its function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

The challenge of new drug discovery for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Bacterial proteolytic complexes as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Comparative genomics of mycobacterial proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Genes required for mycobacterial growth defined by high density mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Biosynthesis and structures of cyclomarins and cyclomarazines, prenylated cyclic peptides of marine actinobacterial origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Structural Basis of Mycobacterial Inhibition by Cyclomarin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

The magic bullets and tuberculosis drug targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

The WHO 2014 global tuberculosis report--further to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Advances in the development of new tuberculosis drugs and treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10295-015-1709-3

Mode of action of ethambutol on Mycobacterium tuberculosis, strain H37R V.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26586403

12 December 2020

inferred from PubMed ID database lookup

Global tuberculosis control: lessons learnt and future prospects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26586403

12 December 2020

inferred from PubMed ID database lookup

Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26586403

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10295-015-1709-3

1 reference

release_n57kpmtes5ditpfzhh6gbqraea

5 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n57kpmtes5ditpfzhh6gbqraea

24 November 2022

mapped directly with Wikidata item

PubMed ID

26586403

1 reference

PubMed ID

26586403